Given its global network of partners and not-for-profit designation

The establishment and resulting efforts of the TB Alliance and the emergence of global philanthropy has lowered the obstacles to TB drug development. Over the last decade, there has been significant development of a global TB drug pipeline. With multiple compounds now in clinical development, an approach whereby new compounds are tested in combination in order to find the best novel regimens or building blocks of novel regimens has emerged as the gold standard of TB drug development.

Given its global network of partners and not-for-profit designation, the TB Alliance is uniquely positioned and leads the field's regimen development efforts, testing the most promising treatments together, regardless of sponsor. In 2010, the TB Alliance launched the first regimen clinical trial, whereby novel TB drug regimens — not single drugs — are the unit of development. In 2013, TB Alliance completed a second, larger and longer trial, also testing multiple new drugs in combination — this time in both TB and MDR-TB patients. Results of these trials validate this approach to TB research. Regimen-based development is integrated not only into the TB Alliance's clinical testing efforts, but into its preclinical research paradigm as well, to facilitate early identification of the building blocks and combinations of building blocks for tomorrow's TB regimens.see more video